close
close
migores1

Terns: Obesity Progress Continues with Another T1 2025 Program Catalyst (TERN)

This article was written by

Profile picture of Terry Chrisomalis

Terry Chrisomalis is a private equity investor in the biotechnology sector with years of experience using his expertise in applied sciences to drive long-term value from healthcare.

He is the author of the Biotech Analysis Central investment group, which contains a library of over 600 Biotech investment articles, a model portfolio of over 10 small- and mid-cap stocks with in-depth analysis for each, live chat and a range of analysis and news. reports to help healthcare investors make informed decisions.

Analyst Disclosure: We do not/have any equity, option or similar derivative positions in any of the companies mentioned and do not intend to initiate such positions in the next 72 hours. I wrote this article myself and it expresses my own opinions. I receive no compensation for this (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Looking for Alpha’s reveal: Past performance is no guarantee of future results. No recommendation or advice is given to determine whether any investment is suitable for any particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, a US broker or investment adviser, or an investment bank. Our analysts are third-party authors that include both professional and individual investors who may not be authorized or certified by any institute or regulatory body.

Related Articles

Back to top button